called amyloid hypothesis argues effective alzheimer treatment depends reducing buildup protein called beta amyloid brain drugs aimed beta amyloid failed benefit biogen shelved aducanumab studies spring took decision proof amyloid hypothesis dominated alzheimer research world decades failed company resurrection aducanumab breathed new life line research biogen october reassessing march finding applying fda approval market aducanumab patients early stage alzheimer not drug approved treat disease 2003 aducanumab aimed modifying progression symptoms thursday conference included cohen high profile alzheimer researchers physicians treated patients trials said agreed biogen analysis data patients seen good results drug eager start taking biogen planning follow study allow